TAVI Protocol - Paravertebral Block Study (TAVI PVB)
Aortic Valve Replacement, Aortic Stenosis
About this trial
This is an interventional treatment trial for Aortic Valve Replacement focused on measuring Delirium, PVB, PCA, Opioid, Aortic Valve replacement
Eligibility Criteria
Inclusion Criteria:
- Consenting subjects who are scheduled to undergo the TAVI surgical procedure
Exclusion Criteria:
- patients with symptomatic cerebrovascular disease,
- history of delirium and schizophrenia
Sites / Locations
- Toronto General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Paravertebral Block
Standard intravenous opioid analgesia
Patients randomized to receive PVB will have a continuous thoracic paravertebral block using local anesthetic after trans-apical aortic valve replacement. The patient will be placed in lateral decubitus position and under aseptic conditions the skin entry points will be 2.5-3cm from the spinal processes of the vertebra at a level of the proposed surgical incision. A 17G Touhy needle will be inserted perpendicular to the skin until the transverse process is contacted. After negative aspiration test an initial bolus of 8ml of plain ropivacaine 0.5% will be administered. This will be followed by a continuous infusion of 0.2% ropivacaine at 10 mL/hr. For break through pain additional doses of ropivacaine will be administered as required.
Patient Controlled Analgesia (PCA) : PCA: the patients who are randomized to PCA group will receive standard of care for this modality.